Refine
Year of publication
Document Type
- Article (37)
- Conference Proceeding (2)
- Preprint (1)
Keywords
- Hematology (7)
- Cancer Research (5)
- Oncology (5)
- General Medicine (4)
- Biochemistry (2)
- Biological Psychiatry (2)
- Cell Biology (2)
- General Biochemistry, Genetics and Molecular Biology (2)
- General Chemistry (2)
- Immunology (2)
Institute
- Medizinische Fakultät (34)
- Universitätsklinikum (31)
- Professur für Transplantation und Zelltherapieforschung (13)
- Lehrstuhl für Innere Medizin mit Schwerpunkt Hämatologie und Onkologie (10)
- Fakultät für Angewandte Informatik (5)
- Institut für Informatik (4)
- Nachhaltigkeitsziele (4)
- Ziel 3 - Gesundheit und Wohlergehen (4)
- Lehrstuhl für Allgemein- und Viszeralchirurgie (3)
- Lehrstuhl für Psychiatrie und Psychotherapie (3)
Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders
(2009)
Background: Pulmonary metastasectomy (PM) is the most frequently performed local ablative therapy for leiomyosarcoma (LMS), synovial sarcoma (SyS), and undifferentiated pleomorphic sarcoma (UPS). This study aimed to assess surgical feasibility, outcome, and clinical prognostic factors, as well as the value of a peri-interventional systemic therapy.
Methods: This multicenter retrospective study enrolled 77 patients with LMS, SyS, or UPS who underwent first-time complete resection of isolated lung metastases between 2009 and 2021. Disease-free survival (DFS), overall survival (OS), and clinical prognostic factors were analyzed.
Results: After the first PM, the median DFS was 7.4 months, and the median OS was 58.7 months. A maximal lesion diameter greater than 2 cm was associated with reduced DFS in both the univariable (hazard ratio [HR], 2.29; p = 0.006) and multivariable (HR, 2.60; p = 0.005) analyses. The univariable analysis identified a maximal lesion diameter greater than 2 cm as an adverse prognostic factor for OS (HR, 5.6; p < 0.001), whereas a treatment-free interval longer than 12 months was associated with improved OS (HR, 0.42; p = 0.032). The addition of systemic therapy was associated with a trend toward improved DFS for patients with lesions larger than 2 cm (HR, 0.29; p = 0.063). Severe postoperative complications (grade ≥IIIa) occurred in 2 % of the patients.
Conclusion: The size of resected lung metastases might be a more relevant prognostic factor than their number for patients with LMS, SyS, or UPS. For patients with lung metastases larger than 2 cm in maximal diameter, additional systemic therapy may be warranted.
In emergency medicine, timely intervention for patients at risk of suicide is often hindered by delayed access to specialised psychiatric care. To bridge this gap, we introduce a speech-based approach for automatic suicide risk assessment. Our study involves a novel dataset comprising speech recordings of 20 patients who read neutral texts. We extract four speech representations encompassing interpretable and deep features. Further, we explore the impact of gender-based modelling and phrase-level normalisation. By applying gender-exclusive modelling, features extracted from an emotion fine-tuned wav2vec2.0 model can be utilised to discriminate high- from low suicide risk with a balanced accuracy of 81%. Finally, our analysis reveals a discrepancy in the relationship of speech characteristics and suicide risk between female and male subjects. For men in our dataset, suicide risk increases together with agitation while voice characteristics of female subjects point the other way.
Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin’s lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. Methods: To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. Results: We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no – or low quality – clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. Conclusion: The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome.
